BRPI1013025A2 - terapia vacínica para neovascularização coroide - Google Patents

terapia vacínica para neovascularização coroide

Info

Publication number
BRPI1013025A2
BRPI1013025A2 BRPI1013025A BRPI1013025A BRPI1013025A2 BR PI1013025 A2 BRPI1013025 A2 BR PI1013025A2 BR PI1013025 A BRPI1013025 A BR PI1013025A BR PI1013025 A BRPI1013025 A BR PI1013025A BR PI1013025 A2 BRPI1013025 A2 BR PI1013025A2
Authority
BR
Brazil
Prior art keywords
choroidal neovascularization
vaccine therapy
vaccine
therapy
choroidal
Prior art date
Application number
BRPI1013025A
Other languages
English (en)
Portuguese (pt)
Inventor
Motokazu Tsujikawa
Takuya Tsunoda
Yusuke Nakamura
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of BRPI1013025A2 publication Critical patent/BRPI1013025A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60N—SEATS SPECIALLY ADAPTED FOR VEHICLES; VEHICLE PASSENGER ACCOMMODATION NOT OTHERWISE PROVIDED FOR
    • B60N2/00—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles
    • B60N2/02—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable
    • B60N2/22—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable
    • B60N2/225—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms
    • B60N2/2252—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms in which the central axis of the gearing lies inside the periphery of an orbital gear, e.g. one gear without sun gear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Mechanical Engineering (AREA)
  • Aviation & Aerospace Engineering (AREA)
  • Transportation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI1013025A 2009-06-11 2010-06-10 terapia vacínica para neovascularização coroide BRPI1013025A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009140363 2009-06-11
PCT/JP2010/003871 WO2010143435A1 (en) 2009-06-11 2010-06-10 Vaccine therapy for choroidal neovascularization

Publications (1)

Publication Number Publication Date
BRPI1013025A2 true BRPI1013025A2 (pt) 2016-04-05

Family

ID=43308696

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013025A BRPI1013025A2 (pt) 2009-06-11 2010-06-10 terapia vacínica para neovascularização coroide

Country Status (14)

Country Link
US (1) US8975229B2 (enExample)
EP (1) EP2440226A4 (enExample)
JP (1) JP5688587B2 (enExample)
KR (1) KR20120038419A (enExample)
CN (1) CN102802654A (enExample)
AU (1) AU2010259797B2 (enExample)
BR (1) BRPI1013025A2 (enExample)
CA (1) CA2764562A1 (enExample)
IL (1) IL216402A0 (enExample)
MX (1) MX2011012659A (enExample)
RU (1) RU2555345C2 (enExample)
SG (2) SG10201403109VA (enExample)
TW (1) TW201109029A (enExample)
WO (1) WO2010143435A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2289532A1 (en) 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
ES2405763T3 (es) * 2007-02-16 2013-06-03 Oncotherapy Science, Inc. Vacunoterapia para la neovascularización coroidea
FR2990352A1 (fr) 2012-05-10 2013-11-15 Univ Paris 13 Composition immunogene comprenant un peptide derive du vegf et ses utilisations
CN110612115A (zh) * 2017-05-19 2019-12-24 学校法人庆应义塾 针对脑神经疾病的肽疫苗和肽疫苗组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6348333B1 (en) 1997-01-17 2002-02-19 Toa Gosei Co., Ltd. VEGF-binding KDR polypeptide
JP4405597B2 (ja) 1997-06-18 2010-01-27 メルク エンド カムパニー インコーポレーテッド ヒト受容体型チロシンキナーゼｋｄｒ
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
CA2328893A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
WO2001012809A2 (en) 1999-08-13 2001-02-22 Crucell Holland B.V. Heterodimeric vegf variants used for inhibiting angiogenesis
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AU2002362461A1 (en) 2001-10-01 2003-04-14 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
CU23178A1 (es) 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
EP2267023B1 (en) 2002-09-12 2015-02-11 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
SI1539157T1 (sl) 2002-09-18 2013-11-29 Trustees Of The University Of Pennsylvania Rapamicin za uporabo pri inhibiciji ali preprečevanju horoidalne neovaskularizacije
ES2687645T3 (es) 2003-10-27 2018-10-26 Merck Sharp & Dohme Corp. Método de diseño de ARNip para el silenciamiento de genes
JP2006215988A (ja) * 2005-02-07 2006-08-17 Ntt Docomo Kansai Inc 認証システム、携帯端末装置及び認証方法
EP2289532A1 (en) 2005-02-28 2011-03-02 Oncotherapy Science, Inc. Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
JP2006315988A (ja) 2005-05-11 2006-11-24 Mototake Shimizu ケモカイン産生誘導効果を有する血管新生阻害物質
ES2405763T3 (es) 2007-02-16 2013-06-03 Oncotherapy Science, Inc. Vacunoterapia para la neovascularización coroidea
JP5272134B2 (ja) 2007-06-14 2013-08-28 オンコセラピー・サイエンス株式会社 Ｓｍｙｄ３によるｖｅｇｆｒ１のメチル化調整因子を同定する方法
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌

Also Published As

Publication number Publication date
JP2012529423A (ja) 2012-11-22
TW201109029A (en) 2011-03-16
KR20120038419A (ko) 2012-04-23
EP2440226A1 (en) 2012-04-18
EP2440226A4 (en) 2013-09-18
MX2011012659A (es) 2011-12-16
IL216402A0 (en) 2012-01-31
SG176737A1 (en) 2012-01-30
CA2764562A1 (en) 2010-12-16
SG10201403109VA (en) 2014-10-30
WO2010143435A1 (en) 2010-12-16
JP5688587B2 (ja) 2015-03-25
RU2012100241A (ru) 2013-07-20
AU2010259797A1 (en) 2011-12-08
US20120156233A1 (en) 2012-06-21
CN102802654A (zh) 2012-11-28
US8975229B2 (en) 2015-03-10
RU2555345C2 (ru) 2015-07-10
AU2010259797B2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
BR112013033444A2 (pt) formulações para terapia de ferida
HRP20190576T1 (hr) Postupci pripreme konjugata
EP2663304A4 (en) COMBINATION THERAPY
DK2709667T3 (da) Bio-orthogonal lægemiddelaktivering
EP2429585A4 (en) VACCINE IMMUNOTHERAPY
DK3170508T3 (da) Vaccineformuleringer
DK2768479T3 (da) Hjælpestoffer til nikotin-indeholdende terapeutiske sammensætninger
BR112012004807A2 (pt) vacina para pcsk9
PT2515855E (pt) Terapêutica de combinação para dpoc
DK2760886T3 (da) Immunocytokin-kombinationsterapi
EP2726095A4 (en) COMBINATION THERAPY
EP2595653A4 (en) INFLUENZA VACCINE
FI20115876A0 (fi) Yhdistelmähoito
EP2748299A4 (en) Targeting microbubbles
BR112014001657A2 (pt) suporte para partes do corpo humano
HUE044772T2 (hu) Immunogén készítmény
EP2640417A4 (en) MULTIVALENCE VACCINE AGAINST FILARIOSIS
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
BR112014005756A2 (pt) vacina
ZA201402071B (en) Vaccine therapy
IL229081A0 (en) Isoxazolines as therapeutic agents
CO6880064A2 (es) Métodos terapéuticos
EP2771453A4 (en) DIATOM-BASED VACCINES
HUE043129T2 (hu) Vakcina intrauterin betegség ellen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]